AU2008265898B2 - Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties - Google Patents

Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties Download PDF

Info

Publication number
AU2008265898B2
AU2008265898B2 AU2008265898A AU2008265898A AU2008265898B2 AU 2008265898 B2 AU2008265898 B2 AU 2008265898B2 AU 2008265898 A AU2008265898 A AU 2008265898A AU 2008265898 A AU2008265898 A AU 2008265898A AU 2008265898 B2 AU2008265898 B2 AU 2008265898B2
Authority
AU
Australia
Prior art keywords
alkyl
heterocycle
alkenyl
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008265898A
Other languages
English (en)
Other versions
AU2008265898A1 (en
Inventor
Edgar Cook (Dec)
Rafal Kaminski
John Kepler
Hernan Navarro
Matthew Orr
Michael Rogawski
Scott P. Runyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International
Office of Technology Transfer
Original Assignee
RTI International
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International, Government of the United States of America filed Critical RTI International
Publication of AU2008265898A1 publication Critical patent/AU2008265898A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, RESEARCH TRIANGLE INSTITUTE reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Request for Assignment Assignors: COOK, KEVIN, KAMINSKI, RAFAL, KEPLER, JOHN, NAVARRO, HERNAN, ORR, MATTHEW, ROGAWSKI, MICHAEL, RUNYON, Scott
Application granted granted Critical
Publication of AU2008265898B2 publication Critical patent/AU2008265898B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2008265898A 2007-06-15 2008-06-16 Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties Ceased AU2008265898B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94425707P 2007-06-15 2007-06-15
US60/944,257 2007-06-15
PCT/US2008/067059 WO2008157460A1 (en) 2007-06-15 2008-06-16 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Publications (2)

Publication Number Publication Date
AU2008265898A1 AU2008265898A1 (en) 2008-12-24
AU2008265898B2 true AU2008265898B2 (en) 2013-11-28

Family

ID=40156649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008265898A Ceased AU2008265898B2 (en) 2007-06-15 2008-06-16 Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties

Country Status (7)

Country Link
US (3) US8575375B2 (enExample)
EP (1) EP2155204B1 (enExample)
JP (3) JP5663303B2 (enExample)
AU (1) AU2008265898B2 (enExample)
CA (1) CA2698172C (enExample)
ES (1) ES2589139T3 (enExample)
WO (1) WO2008157460A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
DK2935307T3 (en) * 2012-12-18 2018-07-30 Univ Washington NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CN117304245A (zh) * 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
AR105044A1 (es) 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
KR20200016410A (ko) * 2016-08-30 2020-02-14 리즈 인코포레이티드 제거 가능한 지지 구조를 갖는 3차원 물체의 제조 방법
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
US12337004B2 (en) 2019-04-27 2025-06-24 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途
EP4153182A4 (en) * 2020-05-18 2024-05-29 Vistagen Therapeutics, Inc. TREATMENT OF ADAPTATION DISORDERS
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143736A (en) * 1994-02-14 2000-11-07 Cocensys, Inc. Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2753361A (en) * 1955-02-01 1956-07-03 Searle & Co 17-thio-5-androstene-3-ols
US2763669A (en) * 1955-03-01 1956-09-18 Searle & Co delta-17-thio-androsten-3-ones
US2847427A (en) * 1957-09-09 1958-08-12 Searle & Co Delta or 5,16 androstadien-17-alkylsulfones and sulfoxides
US3001986A (en) * 1960-07-14 1961-09-26 Searle & Co 3-oxygenated 17 - amino - 17 - carboxyethylandrostane lactams and delta4 compounds corresponding
US3094522A (en) * 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
US3094521A (en) * 1961-07-25 1963-06-18 Merck & Co Inc Alkanoylthio and pyrazolo androstane derivatives
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
CA2698172C (en) 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143736A (en) * 1994-02-14 2000-11-07 Cocensys, Inc. Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series

Also Published As

Publication number Publication date
US20140094619A1 (en) 2014-04-03
JP5663303B2 (ja) 2015-02-04
EP2155204A4 (en) 2011-05-25
WO2008157460A8 (en) 2010-03-25
JP2015003925A (ja) 2015-01-08
US20170051008A1 (en) 2017-02-23
EP2155204B1 (en) 2016-08-17
JP2010530004A (ja) 2010-09-02
ES2589139T3 (es) 2016-11-10
EP2155204A1 (en) 2010-02-24
US20110092473A1 (en) 2011-04-21
CA2698172A1 (en) 2008-12-24
CA2698172C (en) 2014-02-18
US8575375B2 (en) 2013-11-05
WO2008157460A1 (en) 2008-12-24
US10087211B2 (en) 2018-10-02
JP5990557B2 (ja) 2016-09-14
US9518080B2 (en) 2016-12-13
JP5828159B2 (ja) 2015-12-02
JP2015007128A (ja) 2015-01-15
AU2008265898A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
EP2155204B1 (en) Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
AU780989B2 (en) 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
EP2456781B1 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten
EP0404283B1 (de) 11-Beta-aryl-4-estrene, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US5583239A (en) Antimicrobial sterol conjugates
Gupta et al. Synthesis and biological activity of azasteroidal [3, 2-c]-and [17, 16-c] pyrazoles
NO311646B1 (no) Androstenderivater
KR890000678B1 (ko) 소염 작용을 가진 17,17-비스(치환티오)안드로스텐 및 그의 제조방법
JPH08508278A (ja) 新規プレドニソロン誘導体
FI89055C (fi) Foerfarande foer framstaellning av nya androstan-17-karboxylsyraestrar
KR100450854B1 (ko) α-17치환체가없는신규의프레그난유도체,이들의의약용도,제조방법,및이의중간체및관련화합물
JP5731397B2 (ja) ３，５−セコ−４−ノル−コレスタンの新規オキシム誘導体、それを含む医薬組成物、及びその調製方法
EP1196428B1 (en) 11-beta-aryl-17,17-spirothiolane-substituted steroids
RU2257391C2 (ru) Производные фузидовой кислоты, стереоизомер, фармацевтические композиции, соединения
WO2001044267A1 (de) 11-β-PHENYLESTRADIEN-DERIVATE MIT FLUORALKYLGRUPPEN IN DER AROMATISCHEN SEITENKETTE, DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
DE1947221A1 (de) 3-Aza-19-hydroxy-3,19-cyclo-A-homosteroide und ein Verfahren zu deren Herstellung
WO2007062876A1 (de) Prodrugs er-beta-selektiver substanzen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
GB2093838A (en) Dodecahydro benz(E) inden-7- one medicaments

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RESEARCH TRIANGLE INSTITUTE; THE UNITED STATES OF

Free format text: FORMER APPLICANT(S): RUNYON, SCOTT; KEPLER, JOHN; COOK, KEVIN; KAMINSKI, RAFAL; NAVARRO, HERNAN; ROGAWSKI, MICHAEL; ORR, MATTHEW

TH Corrigenda

Free format text: IN VOL 24, NO 28, PAGE(S) 3214 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2008 UNDER THE NAME SCOTT RUNYON; MICHAEL ROGAWSKI; JOHN KEPLER; HERNAN NAVARRO; RAFAL KAMINSKI; MATTHEW ORR; KEVIN COOK, APPLICATION NO. 2008265898, CORRECT THE APPLICANTS TO RESEARCH TRIANGLE INSTITUTE; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER NATIONAL INSTITUTES OF HEALTH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired